In 2006, IAVI and its Neutralizing Antibody Consortium launched the Protocol G project to search for bNAbs against HIV, partnering with clinical research centers in Africa, India, Thailand, Australia, the United Kingdom, and the United States. More than 1,800 healthy, HIV-positive volunteers contributed blood samples to be screened. In 2009, scientists from IAVI, The Scripps Research Institute, and Theraclone Sciences collaborated to isolate and characterize the first new bNAbs to HIV seen in a decade and the first to be isolated from donors in developing countries, where the majority of new HIV infections occur. To date, more than 25 new bNAbs have been isolated and characterized from Protocol G specimens, and many have been shared with researchers across the AIDS vaccine field.
Prevalence / cross-sectional
Varies across multiple sites
Uganda;Zambia;Rwanda;South Africa;Kenya;India;Thailand;Nigeria;Australia;United Kingdom;USA;Ivory Coast
Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI)-Entebbe, Uganda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; YRG Care, Chennai, India; Vaccine Trial Centre, Mahidol University, Bangkok, Thailand; Centre de Diagnostic et de Recherche sur le SIDA et les infections opportunistes (CeDReS), CHU Treichville, BP V3, Abidjan, Côte d’Ivoire; Institute of Human Virology (IHV), Nigeria; National Serology Reference Laboratory (NRL), Australia; St. Stephen’s Centre, London, UK; SUNY Downstate Medical Center, Brooklyn, NY; AFRIMS (Armed Forces Research Institute of Medical Sciences), Bangkok, Thailand.
To generate broadly neutralizing monoclonal antibodies (mAbs) from volunteers who are HIV infected and have broadly cross-reactive serum neutralizing activity.